imsidolimab
imsidolimab: developed by 1 company · 7 clinical trials tracked.
imsidolimab evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could imsidolimab → ANAB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| ANAPTYSBIO, INC (ANAB) | BLA Filed |
Clinical Trials (7)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Primary endpoint: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
Primary endpoint: Change From Baseline in AN Count at Week 16: Placebo-Controlled Period
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Primary endpoint: Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Neoplasm Receiving EGFRi or MEKi Therapy
Primary endpoint: Change From Baseline in Facial Inflammatory Lesion Count (Papules and Pustules) at Week 8
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
Primary endpoint: Change From Baseline in Ichthyosis Area Severity Index (IASI) Total Score at Week 16
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
Primary endpoint: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI)
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
Primary endpoint: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale
Frequently asked questions
Who is developing imsidolimab?
imsidolimab is being developed by ANAPTYSBIO, INC.
How many clinical trials involve imsidolimab?
BioSniper tracks 7 clinical trials involving imsidolimab.